KARACHI: Profits at Pakistan’s listed pharmaceutical companies climbed 28% year-on-year to Rs42.2 billion in FY26, supported mainly by higher medicine prices and reduced financing costs, according to a sector report.
Combined net sales grew 10% to Rs377.9bn, up from Rs342.6bn in FY25. Fourth-quarter sales rose 3% year-on-year to Rs88.9bn.
The sector’s gross margin reached a record 42.8% for FY26, compared with 38.9% a year earlier. In the fourth quarter, margins were 42.8%, against 40.4% in the same period last year and 42.7% in the preceding quarter. The report linked the gains primarily to higher prices.
The stronger financial results come as patients and consumer groups remain concerned about the affordability of medicines. Repeated price increases have added to costs for households, especially people who rely on essential drugs for chronic conditions.
The report said medicine prices rose by about 50% in 2024 and a further 30% to 40% in 2025. It also cited the general sales tax on medicines as an additional burden for consumers.
